Results 141 to 150 of about 38,006 (217)

SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-Analysis. [PDF]

JACC Adv
Spadafora L, Bernardi M, Sarto G, Simeone B, Rocco E, Carbone S, Dalla Vecchia LA, Pedretti RFE, Valenti V, Di Mario R, Forte M, Frati G, Abbate A, Golino M, Versaci F, Peruzzi M, Sabouret P, Biondi Zoccai G, Sciarretta S.   +18 more
europepmc   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source

SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review. [PDF]

Int J Mol Sci
Confederat LG, Pînzariu AC, Serban IL, Condurache MI, Dragostin OM.   +4 more
europepmc   +1 more source

Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Rosa Yang, Kevin Cho, Max C. Petersen, Kai E. Jones, Gary J. Patti, Janet B. McGill, Samantha A. DiGruccio   +6 more
wiley   +1 more source

MicroRNAs and SGLT2 inhibitors in cardiovascular disease: Shared pathways and emerging roles. [PDF]

J Mol Cell Cardiol Plus
Bhaskaran AB, Sakr A, Doycheva D.
europepmc   +1 more source

Response to “Methodological Considerations in Interpreting Renal [18F]FDG‐PET After Short‐Term Dapagliflozin Treatment”

Diabetes, Obesity and Metabolism, EarlyView.
Shawn Gugliandolo, Patricia Iozzo, Lucia Leccisotti, Francesca Cinti   +3 more
wiley   +1 more source

HIV‐associated nephropathy: A decade of clinical outcomes, global disparities and emerging promise

HIV Medicine, EarlyView.
Abstract Objective To review the pathogenesis, epidemiology, clinical presentation, management and outcomes of HIV‐associated nephropathy (HIVAN), with emphasis on global disparities, genetic susceptibility (APOL1) and emerging therapeutic and technological advances.
Deepak V. Pathiyil, Nicola Wearne, Brendon Price, Frank Post, Dami A. Collier   +4 more
wiley   +1 more source

Impact of SGLT2 inhibitors in cardiac amyloidosis: A systematic review and meta-analysis. [PDF]

Am Heart J Plus
Nandyal S, Vij A, Varma R, Gajjar R, Caputi A, Odoi S, Banthiya S, Vinjamuri S, Malhotra S.   +8 more
europepmc   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis. [PDF]

Front Pharmacol
Sharma A, Sharma B, Vamaraju DS, Ajay AK.   +3 more
europepmc   +1 more source